Thyrocare FY26: Pathology-led growth, improving margins, and a push into specialty

Thyrocare Technologies closed FY26 with a strong finish in Q4. Consolidated revenue for Q4FY26 rose 20% year-on-year to INR 223.95 crore. Profitability improved faster than revenue. Reported EBITDA grew 31% year-on-year to INR 75.09 crore, with a 34% margin. PAT for the quarter was INR 48.70 crore, up 128% year-on-year, aided by a higher base impact last year due to exceptional items.

For the full year, consolidated revenue reached INR 829.04 crore, up 21% year-on-year. Reported EBITDA was INR 262.04 crore, up 38%, translating to a 32% margin. PAT increased 81% to INR 162.85 crore, with a 20% margin. Management framed FY26 as a year of building scale while tightening the operating backbone, especially on quality and turnaround time.

What drove the quarter: pathology stayed dominant

The topline was driven by the core pathology business. In Q4FY26, consolidated pathology revenue was INR 211.5 crore, while radiology revenue was INR 12.4 crore. The presentation showed radiology revenue declining year-on-year, and management attributed this to strategic consolidation of centres during the year.

Within pathology, the franchise channel and partnership channel both expanded. The presentation’s channel split for Q4FY26 showed franchise pathology revenue of INR 127.6 crore, partnerships at INR 71.6 crore and D2C at INR 11.5 crore. Management also clarified that partnership growth in Q4 looks softer because Q4FY25 had a one-off uplift of around INR 4 crore from camps and early insurance traction, and that normalised partnership growth would have been closer to 32%.

Financial snapshot

Volume growth and network expansion supported operating leverage

Operationally, FY26 showed steady scaling. The presentation reported 209.6 million tests conducted in FY26, up 23% year-on-year, and 19.2 million patients, up 15%. Revenue per test remained broadly stable at INR 36.1, while revenue per patient increased to INR 395. Tests per patient rose to 10.9, suggesting a gradual shift towards broader test baskets.

Network growth was a key enabler. Active franchisees reached about 10,800 in Q4FY26, up 15% year-on-year. Management reiterated that franchise expansion remains a central growth lever and described the business as asset-light because collection points are franchise-owned. The company also expanded the lab network to 40 labs in India plus one in Tanzania, opening seven new labs in FY26 across Bhagalpur, Mandi, Roorkee, Kashmir, Davanagere, Vijayawada and Gwalior.

A notable theme in management commentary was that growth is not constrained by lab capex. Management stated average lab utilisation is about 65%, and that most of the growth is expected to come from franchise additions and higher productivity in the installed base.

Quality, turnaround time, and specialty expansion

Thyrocare positioned quality and speed as core differentiators. In Q4FY26, 97% of samples were processed in NABL-accredited owned laboratories. The company reported an average turnaround time of 3.43 hours from sample receipt and complaints of 3.06 per million tests for Q4, which management described as Six Sigma levels.

Alongside the core, the company is expanding into specialty diagnostics. FY26 saw allergy testing brought in-house using the Phadia platform, and management stated the allergy menu now has over 250 SKUs. The company also entered genomics on May 1, starting with non-invasive prenatal testing under the HerCheck NIPT offering. Management described a phased approach focused on defined panels, clinical validation and education before scaling.

Management also offered a medium-term directional target: specialty mix could reach 15% to 20% in about three years, broadly in line with peers. However, they cautioned that specialty will be priced aggressively and may not lift EBITDA margins in FY27.

Cash generation, capital allocation, and key watch-outs

Cash generation remained healthy. FY26 operating cash flow was INR 213.24 crore. The company paid dividends of INR 148.43 crore during FY26, and management also noted that the board recommended a final dividend of INR 7 per equity share. The CFO stated the balance sheet remains debt-free with net cash and investments of INR 230 crore plus as of March 31, 2026.

On guidance, management commentary stayed conservative on margins and pricing. They indicated gross margins are expected to be in the 73% to 74% range. They also guided to mid to high teens growth expectation for next year, driven largely by volumes, with no intention to increase prices.

Risks and weaker spots were also acknowledged. Tanzania has not broken even, though management said quarterly losses are less than INR 1 crore. Radiology revenue declined due to consolidation, and the CFO stated the tax rate may move to 28% to 29% going forward due to deferred tax timing differences.

Takeaways

FY26 reinforced Thyrocare’s core positioning as a scaled, B2B-focused diagnostics platform led by pathology. The company combined strong revenue growth with margin improvement, backed by network expansion, tighter quality metrics and faster turnaround times. The next phase hinges on whether specialty and genomics initiatives can scale without disrupting the company’s affordability-led model and whether radiology stabilises after the consolidation phase.